Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

G. Fowler, Vance; Das, Anita; Lipka-Diamond, Joy; Schuch, Raymond; J. Pomerantz, Roger; Jáuregui-Peredo, Luis; Bressler, Adam; C. Evans, David; J. Moran, Gregory; E. Rupp, Mark; A. Wise, Robert; Ralph Corey, G.; Zervos, Marcus; S. Douglas, Pamela; Cassino, Cara

doi:10.1172/jci136577

Public

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

Published in Journal of Clinical Investigation • Apr 9, 2020

Authors:

Vance G. Fowler

Anita Das

Joy Lipka-Diamond

Abstract

BACKGROUNDNovel therapeutic approaches are critically needed for Staphylococcus aureus bloodstream infections (BSIs), particularly for methicillin-resistant S. aureus (MRSA). Exebacase, a first-in-class antistaphylococcal lysin, is a direct lytic agent that is rapidly bacteriolytic, eradicates biofi...

Subject

Bloodstream infection

Staphylococcus aureus

Endocarditis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!